Project Grant F32AI200229
Award Date 11/19/26
Completion Date 6/30/29
Dollars Obligated $159K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $149,190 on January 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate R-pyocins as a therapeutic approach to treat high-risk, multidrug-resistant Pseudomonas aeruginosa wound infections. The project addresses the rising prevalence of multidrug-resistant and extensively drug-resistant P. aeruginosa strains that cause acute and chronic infections from...
- The National Institute of Allergy and Infectious Diseases awarded $825,054 to Trustees of Dartmouth College on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how a dual-function Type VI secretion system immunity protein affects airway microbiota composition and pathogen fitness. The research examines the T6SS effector TSET and its cognate immunity protein TSIT in Pseudomonas aeruginosa, which causes chronic respiratory infections in...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $224,857 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a cystic fibrosis ferret model of chronic Mycobacterium abscessus lung infection. The award funds development of a novel animal model to study disease pathogenesis and test antimicrobial therapies targeting M. abscessus infection in people with cystic fibrosis....
- The National Institute of Allergy and Infectious Diseases awarded New York University $712,258 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct comparative investigation of two carboxyl-terminal processing proteases (CTPs) in Pseudomonas aeruginosa, a pathogen responsible for acute pneumonia, severe wound infections, and chronic lung colonization in cystic fibrosis patients. The research examines the contrasting roles and mechanisms of PRC and...
- The National Institute of Allergy and Infectious Diseases awarded California Institute of Technology $711,488 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate maintenance metabolism in Pseudomonas aeruginosa biofilms through phenazine cycling. The research examines how slow- or non-growing bacterial cells conserve and expend energy economically within biofilm aggregates under anoxic conditions. Antibiotic tolerance in chronic...
- The National Institute of Allergy and Infectious Diseases awarded J. Craig Venter Institute, Inc. $529,490 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer a temperate Burkholderia cepacia complex bacteriophage for therapeutic use. The recipient will engineer a prophage designated BCC02, isolated from Burkholderia genomic material, to disable its ability to integrate into bacterial genomes and increase its therapeutic range against bacteria...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $431,784 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on Pseudomonas aeruginosa carriage in the gastrointestinal tract. The funded research investigates how hospitalized patients acquire P. aeruginosa colonization in the GI tract, which serves as a major reservoir for subsequent spread to other body sites and infection. The recipient will...
- The National Institute of Allergy and Infectious Diseases awarded National Jewish Health $164,350 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate glucose and glutamine transport as novel targets in cystic fibrosis immune responses. The research examines solute carrier proteins SLC2A4RG and SLC38A9, which show significant expression changes in CD3+ T cells following triple combination CFTR modulator therapy...
- The National Institute of Allergy and Infectious Diseases awarded $533,850 to the University of Texas at Arlington on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the pathogenesis of Staphylococcus aureus thymidine-dependent small-colony variants in cystic fibrosis patients. The research characterizes how thymidine-dependent small-colony variants, which frequently colonize CF airways following anti-folate antibiotic exposure,...